Based on the Procept Biorobotics Corp stock forecast from 6 analysts, the average analyst target price for Procept Biorobotics Corp is USD 85.40 over the next 12 months. Procept Biorobotics Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Procept Biorobotics Corp is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Procept Biorobotics Corp’s stock price was USD 88.94. Procept Biorobotics Corp’s stock price has changed by -10.23% over the past week, +22.74% over the past month and +165.65% over the last year.
No recent analyst target price found for Procept Biorobotics Corp
No recent average analyst rating found for Procept Biorobotics Corp
Company Overview Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. Read Less
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for us...Read More
Frequently Asked Questions About Procept Biorobotics Corp (PRCT) Stock
Based on ratings from 6 analysts Procept Biorobotics Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on PRCT's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for PRCT is USD 85.40 over the next 12 months. The maximum analyst target price is USD 99 while the minimum anlayst target price is USD 69.
PRCT stock's Price/Earning ratio is 53.06.
Our analysis grades PRCT stock's Price / Earning ratio at F. This means that PRCT stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this PRCT may be a overvalued for its sector.
The last closing price of PRCT's stock was USD 88.94.
The most recent market capitalization for PRCT is USD 4.99B.
Based on targets from 6 analysts, the average taret price for PRCT is projected at USD 85.40 over the next 12 months.
This means that PRCT's stock price may go down by -3.98% over the next 12 months.
We can't find any ETFs which contains Procept Biorobotics Corp's stock.
As per our most recent records Procept Biorobotics Corp has 626 Employees.
Procept Biorobotics Corp's registered address is 150 Baytech Drive, San Jose, CA, United States, 95134.
You can get more information about it from Procept Biorobotics Corp's website at https://www.procept-biorobotics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Procept Biorobotics Corp (PRCT) Stock
Based on ratings from 6 analysts Procept Biorobotics Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on PRCT's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for PRCT is USD 85.40 over the next 12 months. The maximum analyst target price is USD 99 while the minimum anlayst target price is USD 69.
PRCT stock's Price/Earning ratio is 53.06.
Our analysis grades PRCT stock's Price / Earning ratio at F. This means that PRCT stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this PRCT may be a overvalued for its sector.
The last closing price of PRCT's stock was USD 88.94.
The most recent market capitalization for PRCT is USD 4.99B.
Based on targets from 6 analysts, the average taret price for PRCT is projected at USD 85.40 over the next 12 months.
This means that PRCT's stock price may go down by -3.98% over the next 12 months.
We can't find any ETFs which contains Procept Biorobotics Corp's stock.
As per our most recent records Procept Biorobotics Corp has 626 Employees.
Procept Biorobotics Corp's registered address is 150 Baytech Drive, San Jose, CA, United States, 95134.
You can get more information about it from Procept Biorobotics Corp's website at https://www.procept-biorobotics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRCT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
